#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Deafness bilateral Penile squamous cell carcinoma Dupuytren's contracture Non-small cell lung cancer metastatic Craniopharyngioma Osteomyelitis Alport's syndrome Retinopathy of prematurity Infection in an immunocompromised host Round cell liposarcoma Intracranial calcification Dedifferentiated liposarcoma Gastrointestinal stromal tumour Superficial vein thrombosis Small cell lung cancer recurrent More trials…

    Learn about Rare Diseases

    Activated PI3 kinase delta syndrome Cystic fibrosis lung – Diagnostics Haemophilia B without inhibitors – Basic Information Stevens-Johnson syndrome Pulmonary sarcoidosis – Basic Information Extranodal marginal zone B-cell lymphoma (MALT type) Hepatoblastoma – Life with Disease Angelman’s syndrome Alagille syndrome – Basic Information Systemic mastocytosis – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ZELENECTIDE PEVEDOTIN Urokinase Pitavastatin Calcium Cldn6 Rna-Lpx Oteracil Arachis Hypogaea Flour Betula Verrucosa (108) Namodenoson Sertraline Hydrochloride Foscarnet Sodium Hexahydrate Tezacaftor Alizapride SELTOREXANT Mezigdomide Isoniazid Pembrolizumab Infigratinib Olopatadine Axicabtagene Ciloleucel Etanercept More therapies…

    Learn about Your Condition

    Prolymphocytic leukaemia Lymphatic malformation Thromboangiitis obliterans Infectious pleural effusion Myxofibrosarcoma Anaemia of pregnancy Breast cancer metastatic Testicular leiomyosarcoma Desmoplastic melanoma Embolic stroke Craniosynostosis Alagille syndrome Pulmonary sarcoidosis Hip arthroplasty Neurodevelopmental disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Psoriasis

  • A study to evaluate the effectiveness and safety of zasocitinib in children and adolescents with moderate-to-severe plaque psoriasis

    Recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Zasocitinib
    Germany Italy Poland Spain

  • Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Ustekinumab
    • Deucravacitinib
    Belgium Bulgaria Czechia Denmark France Germany +6

  • Study of deucravacitinib compared to placebo in adolescents aged 12-17 years with moderate to severe plaque psoriasis

    Recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Deucravacitinib
    Belgium Germany Hungary Italy Poland Romania +1

  • Study of early versus late risankizumab treatment to evaluate immune cell response in patients with moderate to severe psoriasis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Risankizumab
    Spain

  • Study on Sodium Fluoride (18F) PET-CT Scans for Detecting Bone Changes in Psoriasis Patients at Risk of Psoriatic Arthritis

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Sodium Fluoride (18F)
    The Netherlands

  • Study on Proactive Drug Monitoring with Secukinumab, Ixekizumab, or Guselkumab for Patients with Moderate-to-Severe Psoriasis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Ixekizumab
    • Guselkumab
    • Secukinumab
    Belgium
1 2 3 … 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!